Changes in Perceptions and Confidence of Health Care Professionals across Medical Specialties Regarding Use of SGLT2 and GLP-1 for Cardiorenal Benefit in Type 2 Diabetes

被引：0
|
作者：
Zytnick, Deena
Woolley, Ryan
Bruns, Michelle
Shay, Christina M.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-143-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
143-LB
引用
收藏
页数：3
相关论文
共 50 条
  • [21] SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
    Bloomgarden, Zachary T.
    Handelsman, Yehuda
    ENDOCRINE PRACTICE, 2015, 21 (12) : 1442 - 1444
  • [22] The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
    Azoulay, Laurent
    Simms-Williams, Nikita
    Yin, Hui
    Lu, Sally
    Treves, Nir
    Yu, Oriana Hoi Yun
    DIABETES, 2023, 72
  • [23] SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum
    Preston, Frank G.
    Anson, Matthew
    Riley, David R.
    Ibarburu, Gema H.
    Henney, Alexander
    Lip, Gregory Y. H.
    Cuthbertson, Daniel J.
    Alam, Uazman
    Zhao, Sizheng S.
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 835 - 840
  • [24] Novel Use of SGLT2 inhibitor and GLP-1 agonist in Alstrom syndrome
    Rafferty, S.
    Crowley, M.
    O Halloran, D. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 100 - 100
  • [25] SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)
    Nguyen, Julia
    Nee, Robert
    Marneweck, Hava
    Banaag, Amanda
    Koehlmoos, Tracey
    Oliver, James
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [26] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [27] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Pedro Cardoso
    Katie G. Young
    Anand T. N. Nair
    Rhian Hopkins
    Andrew P. McGovern
    Eram Haider
    Piyumanga Karunaratne
    Louise Donnelly
    Bilal A. Mateen
    Naveed Sattar
    Rury R. Holman
    Jack Bowden
    Andrew T. Hattersley
    Ewan R. Pearson
    Angus G. Jones
    Beverley M. Shields
    Trevelyan J. McKinley
    John M. Dennis
    Diabetologia, 2024, 67 : 822 - 836
  • [28] Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
    Jha, Kunal K.
    Adhikari, Rishav
    Tasdighi, Erfan
    Osuji, Ngozi
    Rajan, Tanuja
    Blaha, Michael J.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 925 - 937
  • [29] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [30] Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control
    Curtis, Louise
    Humayun, Malik Asif
    Walker, James
    Hampton, Kerri
    Partridge, Helen
    PRACTICAL DIABETES, 2016, 33 (04) : 129 - 132
12345